Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04868604 · ClinicalTrials.gov registry record · Phase 1
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
A Phase 1 study of Prostatic Neoplasms, Castration-Resistant, sponsored by Clarity Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 7
- Study locations
NCT04868604: Recruiting Phase 1 study of Prostatic Neoplasms, Castration-Resistant, sponsored by Clarity Pharmaceuticals.
NCT04868604 is a Phase 1 study of Prostatic Neoplasms, Castration-Resistant that is actively recruiting participants, run by Clarity Pharmaceuticals. The registered enrollment target is 54 participants, below the 736-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04868604, a Phase 1 study of Prostatic Neoplasms, Castration-Resistant, is actively recruiting participants, sponsored by Clarity Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 7
- Study locations
Study Summary
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Primary Outcome
Biodistribution will be calculated by utilizing the PET/CT scans.
Conditions Studied
Interventions
- DRUG 64Cu-SAR-bisPSMA
- DRUG 67Cu-SAR-bisPSMA
Study Locations (7)
California
- Stanford Cancer Institute - Stanford
Louisiana
- East Jefferson General Hospital - River Ridge
Michigan
- BAMF Health - Grand Rapids
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine at Barnes-Jewish Hospital - St Louis
Nebraska
- XCancer - Omaha
New York
- Weill Cornell Medicine at New York-Presbyterian - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2026-09 |
| Phase | Phase 1 |
What NCT04868604 shows while recruiting
NCT04868604 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 736-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 2 interventions - of which 64Cu-SAR-bisPSMA is the first listed.
NCT04868604 lists 7 locations in 7 states (California, Louisiana, Michigan).
Frequently Asked Questions
What is clinical trial NCT04868604 about?
NCT04868604 is a clinical study titled "64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)". The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
What is the current status of trial NCT04868604?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2021-08-11. Estimated completion is 2026-09.
What conditions does trial NCT04868604 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.
What interventions are being tested in trial NCT04868604?
The interventions under investigation include: 64Cu-SAR-bisPSMA (DRUG), 67Cu-SAR-bisPSMA (DRUG).
Who is sponsoring clinical trial NCT04868604?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04868604 being conducted?
This trial has 7 study locations across California, Louisiana, Michigan, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms, Castration-Resistant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04868604's enrollment target sits among peer trials
54 8th of 10 higher than 2 of 10 other Prostatic Neoplasms, Castration-Resistant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms, Castration-Resistant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RECRUITING · Phase 1
-
Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RECRUITING · Phase 1
-
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
COMPLETED · Phase 1
-
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI